A Phase II Study for Exploring the Efficacy and Safety of Toripalimab with Anlotinib for Second- or third-line treatment of EGFR-TKI-resistant Patients with Advanced Non-squamous Non-small Cell Lung Cancer
Latest Information Update: 31 Jan 2020
At a glance
- Drugs Catequentinib (Primary) ; Toripalimab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 31 Jan 2020 New trial record